PA8475001A1 - Composiciones estabilizadas - Google Patents

Composiciones estabilizadas

Info

Publication number
PA8475001A1
PA8475001A1 PA19998475001A PA8475001A PA8475001A1 PA 8475001 A1 PA8475001 A1 PA 8475001A1 PA 19998475001 A PA19998475001 A PA 19998475001A PA 8475001 A PA8475001 A PA 8475001A PA 8475001 A1 PA8475001 A1 PA 8475001A1
Authority
PA
Panama
Prior art keywords
magnesium oxide
ace inhibitor
compositions containing
stabilized compositions
quinapril
Prior art date
Application number
PA19998475001A
Other languages
English (en)
Inventor
Daniel Jane Allen
Harris Michael Ray
Hokanson Gerard Cliford
Weiss Jay
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8475001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8475001A1 publication Critical patent/PA8475001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES QUE CONTIENEN INHIBIDOR DE ACE ESTABILIZADAS MEDIANTE LA PRESENCIA DE OXIDO DE MAGNESIO. PREFERENTEMENTE, EL INHIBIDOR DE ACE, QUINAPRIL, ES PROTEGIDO DE CIERTAS FORMAS DE DEGRADACION CUANDO SE PREPARA EN UNA COMPOSICION FARMACEUTICA COMPUESTA ESENCIALMENTE POR OXIDO DE MAGNESIO COMO EL AGENTE ESTABILIZADOR. LA PRESENCIA DE OXIDO DE MAGNESIO TAMBIEN SE PRESTA PARA CONDICIONES DE PROCESAMIENTO FAVORABLES DURANTE LA FABRICACION DE LAS COMPOSICIONES QUE CONTIENEN INHIBIDOR DE ACE, ESPECIALMENTE PROCESAMIENTO MEDIANTE GRANULACION EN MEDIO HUMEDO.
PA19998475001A 1998-06-05 1999-06-04 Composiciones estabilizadas PA8475001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05

Publications (1)

Publication Number Publication Date
PA8475001A1 true PA8475001A1 (es) 2000-09-29

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998475001A PA8475001A1 (es) 1998-06-05 1999-06-04 Composiciones estabilizadas

Country Status (32)

Country Link
US (3) US6417196B1 (es)
EP (1) EP1083931B1 (es)
JP (1) JP3727848B2 (es)
KR (1) KR20010052557A (es)
CN (1) CN1144598C (es)
AR (1) AR019150A1 (es)
AT (1) ATE295184T1 (es)
AU (1) AU755616B2 (es)
BR (1) BR9910947A (es)
CA (1) CA2330581A1 (es)
CO (1) CO5011043A1 (es)
DE (1) DE69925269T2 (es)
ES (1) ES2242398T3 (es)
GT (1) GT199900079A (es)
HK (1) HK1038879B (es)
HN (1) HN1999000088A (es)
HU (1) HUP0102260A3 (es)
ID (1) ID27398A (es)
IL (1) IL139590A0 (es)
IS (1) IS2270B (es)
MY (1) MY119667A (es)
NO (1) NO20006148D0 (es)
NZ (1) NZ508544A (es)
PA (1) PA8475001A1 (es)
PE (1) PE20000543A1 (es)
PL (1) PL344586A1 (es)
SV (1) SV1999000072A (es)
TR (1) TR200003600T2 (es)
TW (1) TW565455B (es)
UY (1) UY25546A1 (es)
WO (1) WO1999062560A1 (es)
ZA (1) ZA200006537B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
KR100741937B1 (ko) * 2000-05-24 2007-07-24 오츠카 세이야쿠 가부시키가이샤 제제의 안정화 방법
ES2283774T3 (es) * 2002-01-15 2007-11-01 Actavis Group Hf. Formulaciones de quinapril e inhibidores de la eca relacionados.
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
MXPA06000226A (es) * 2003-06-26 2006-03-21 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3..0]-octano-3-carboxilico.
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
BRPI0710172A2 (pt) * 2006-04-19 2011-08-23 Teva Pharma composição farmacêutica estável de ácido carboxìlico derivado de 2-aza-biciclo[3,3,0]-octana-3
US20100035955A1 (en) * 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) 1967-05-16 Method of preparing magnesia
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
IS2270B (is) 2007-07-15
TR200003600T2 (tr) 2001-04-20
AR019150A1 (es) 2001-12-26
JP3727848B2 (ja) 2005-12-21
BR9910947A (pt) 2001-03-06
HK1038879B (zh) 2004-10-08
CO5011043A1 (es) 2001-02-28
JP2002516881A (ja) 2002-06-11
GT199900079A (es) 2000-11-25
ES2242398T3 (es) 2005-11-01
CN1304322A (zh) 2001-07-18
EP1083931B1 (en) 2005-05-11
SV1999000072A (es) 2000-05-04
DE69925269D1 (de) 2005-06-16
TW565455B (en) 2003-12-11
WO1999062560A1 (en) 1999-12-09
ATE295184T1 (de) 2005-05-15
US6417196B1 (en) 2002-07-09
HUP0102260A2 (hu) 2002-03-28
NZ508544A (en) 2002-10-25
IS5712A (is) 2000-11-10
CN1144598C (zh) 2004-04-07
PE20000543A1 (es) 2000-08-10
UY25546A1 (es) 1999-09-27
ZA200006537B (en) 2001-11-12
AU3979399A (en) 1999-12-20
MY119667A (en) 2005-06-30
DE69925269T2 (de) 2006-02-23
NO20006148L (no) 2000-12-04
HUP0102260A3 (en) 2002-12-28
ID27398A (id) 2001-04-05
US20060106057A1 (en) 2006-05-18
IL139590A0 (en) 2002-02-10
US20020161020A1 (en) 2002-10-31
EP1083931A1 (en) 2001-03-21
HN1999000088A (es) 2000-02-10
CA2330581A1 (en) 1999-12-09
NO20006148D0 (no) 2000-12-04
KR20010052557A (ko) 2001-06-25
HK1038879A1 (en) 2002-04-04
PL344586A1 (en) 2001-11-05
US7015232B2 (en) 2006-03-21
AU755616B2 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
PA8475001A1 (es) Composiciones estabilizadas
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
BR0012752A (pt) Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
CY1109168T1 (el) Συνθεση νατριουχου φονταπαρινοξης υψηλης καθαροτητας
DK1901755T3 (da) Nye farmaceutiske sammensætninger indeholdende hyaluronsyre eller dens derivater og collagenase til topisk behandling af sår, forbrændinger og ulcera
CR7034A (es) Portador con fibrinogeno solido y trombina solida
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
CO5040140A1 (es) Composiciones detergentes para superficies duras que comp- prenden un polimero hidrofilo a nivel muy bajo que atenua el esfuerzo cortante
AR036652A1 (es) Composiciones para el tratamiento del cabello que brindan cuerpo al cabello y que comprenden adhesivos sensibles a la presion de la silicona
MY120864A (en) Composition for preventing creeping of a flux for soldering and use thereof.
NO20013966D0 (no) Kombinasjoner for behandling av sykdommer som involverer angiogenese
DK1441769T3 (da) Farmaceutiske formuleringer, der indeholder lave koncentrationer af peroxid, til behandling eller forebyggelse af vaginale infektioner
DK1476438T3 (da) Oxa- og thiadiazoler og deres anvendelse som metalloproteinaseinhibitorer
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
DK1408966T3 (da) Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
BRPI0408299A (pt) inibidores de catepsina s
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
AR030416A1 (es) COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
CR8974A (es) Composicion farmaceutica
ECSP992981A (es) Composiciones estabilizadas
ATE359350T1 (de) Verdickte wässrige zusammensetzungen
ATE333796T1 (de) Flüssige antimikrobielle zusammensetzungen